BIOKE and Rain Dance Technologies Announce Distribution Agreement in BeNeLux and Germany
News Nov 27, 2013
“We are starting to see broad adoption of our new innovative RainDrop Digital PCR System across Europe and we look forward to working closely with the BIOKÉ team and sharing our knowledge to better serve our growing number of customers.”
Built on RainDance’s patented and proven RainStorm™ technology, the RainDrop Digital PCR System generates up to 10 million picoliter-sized droplets per lane. Since each droplet encapsulates a single molecule, researchers can quickly determine the absolute number of droplets containing specific target DNA and compare that to the number of droplets with background wild-type DNA. The RainDrop System also shifts the current digital PCR (dPCR) paradigm from a single-color-per-marker approach to a two color with varying probe intensity method that is capable of multiplexing up to 10 markers.
“When I first saw the RainDrop Digital PCR System, I was really impressed with the sensitivity, quantitation and multiplexing capabilities,” stated Koos Kranenborg, Director of Sales at BIOKÉ. “The RainDrop System fits perfectly within the innovative and pioneering product-portfolio of BIOKÉ. We are really looking forward to presenting this innovative droplet-based system to our customer base in the BeNeLux and Germany.”
“We selected BIOKÉ because of its years of experience working with cutting-edge genomics technologies and strong relationships with the key opinion leaders across the BeNeLux region and Germany,” said Sandy McBean, General Manager, Commercial Operations EMEA, RainDance Technologies. “We are starting to see broad adoption of our new innovative RainDrop Digital PCR System across Europe and we look forward to working closely with the BIOKÉ team and sharing our knowledge to better serve our growing number of customers.”
When the Human Genome Project was completed, in 2003, it opened the door to a radical new idea of health - that of personalized medicine, in which disease risk and appropriate treatment would be gleaned from one's genetic makeup. In a new article, researchers discuss how gene interaction networks hold the clues to disease susceptibility and treatment response.READ MORE